HaluGen Life Sciences Inc.

Home
Canada
Vancouver, BC
HaluGen Life Sciences Inc.

Our leading genetic-based psychedelics pre-screening platform helps evaluate your overall sensitivit

05/10/2022

We are delighted to have partnered with Maya Health to promote our Psychedelics Genetic Test Kit.

With a simple cheek swab, our test evaluates your overall sensitivity and risk profile when using psychedelic substances.

Enter ‘maya10’ at checkout for 10% off your test kit.

Be sure to check out Maya Health! Their mission is to harness the power of real world evidence to inform best practices and sensible policies, so that more people can access safe psychedelic practices for healing and expansion.

04/28/2022

Have you heard of the CYP2D6 gene?

CYP2D6 has been found to be a major enzyme responsible for the metabolism of L*D, M**A and ayahuasca.

Identifying a person’s CYP2D6 phenotype can provide insight into their L*D, M**A and ayahuasca response and the potential for adverse drug reactions.

HaluGen’s genetic test identifies an individual’s CYP2D6 phenotype to better identify inter-individual variation in response and adverse reactions to L*D, M**A and ayahuasca.

04/26/2022

Learn how your genetics can impact your psychedelic response. From a simple cheek swab, we provide rapid DNA test results within days.

You’ll also get access to pre-screening surveys and educational resources to help you gain key insights into your psychedelic journey.

04/21/2022

Have you heard of the NRG1 gene?

The NRG1 gene is a promising factor for differentiating high-risk individuals who are at risk for psychosis.

A mutation in the NRG1 gene can affect prefrontal activation and structural connectivity in the brain and is related to the expression of a specific NRG1 isoform.

Over-expression of NRG1 results in a reduction of cortical gray matter volumes, lower synaptic plasticity, and abnormal dendritic spine growth.

Identifying individual variation in NRG1 genotype can provide insight into risk for early onset psychosis and the potential for adverse drug reactions when using psychedelic drugs, particularly those prone to acute psychotic episodes.

HaluGen’s genetic test identifies an individual’s NRG1 genotype to better identify those at risk for adverse consequences that could potentially be triggered by psychedelic usage.

04/19/2022

HaluGen’s genetic test helps to evaluate your overall sensitivity and risk profile when using psychedelic drugs.

But that’s not all, you’ll have access to your personal dashboard where you can view your results along with screening surveys, research papers and other educational resources to help you gain key insights into your psychedelic journey.

04/08/2022

We are delighted to have partnered with Psychedelic Spotlight to promote our Psychedelics Genetic Test Kit.

With a simple cheek swab, our test evaluates your overall sensitivity and risk profile when using psychedelic substances.

Enter ‘PSYCspotlight’ at checkout for 10% off your test kit.

Be sure to subscribe to Psychedelic Spotlight for the latest stories in the emerging psychedelics industry.

04/07/2022

Have you heard of the CYP2B6 gene?

The way your body metabolizes ketamine, a fast-acting anesthetic with hallucinogenic properties, is influenced by the CYP2B6 gene.

This gene encodes a liver enzyme that helps metabolize ketamine in your bloodstream.

10–20% of people carry the CYP2B6*6 genetic variant which causes them to metabolize ketamine up to 2x to 3x slower than normal.

Identifying a person’s CYP2B6 genotype can provide insight into their ketamine response and the potential for adverse drug reactions.

HaluGen’s genetic test identifies an individual’s CYP2B6 genotype to better identify inter-individual variation in response and adverse reactions to ketamine.

04/01/2022

Interested in discovering how you’ll potentially respond to psychedelics?

Our genetic test kit helps to evaluate your overall sensitivity and risk profile when using hallucinogenic drugs.

Order your test today and discover how your genetics can affect your psychedelic experience.

03/29/2022

Our Psychedelics Genetic Test Kit now includes a key pharmacodynamic biomarker, the brain-derived neurotrophic factor (BDNF) gene.

This gene can affect the secretion of BDNF protein, which is released as a result of being dosed with ketamine. BDNF helps with the growth and maintenance of new neurons and synapses that are necessary for normal mood regulation and neural connectivity.

Testing for the BDNF Val66Met genetic polymorphism can better help individual's understand their response to ketamine. Approximately 30% of the population carries the BDNF 'Met' genetic variant, which can impair the secretion of BDNF. These individuals are more likely to have a decreased response to the antidepressant effects of ketamine therapy.

Link to press release in comments.

03/24/2022

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence. Study linked in the comments.

03/22/2022

HaluGen’s genetic test helps to evaluate your overall sensitivity and risk profile when using psychedelics.

You’ll have access to your personal dashboard where you can view your results along with screening surveys, research papers and other educational resources to help you gain key insights into your psychedelic journey.

03/16/2022

Have you heard of the C4A gene?

Excess production of the C4A protein encoded by the C4A gene is associated with an increased risk of aberrant synaptic pruning in the brain, which is a contributing factor to psychotic disorders such as schizophrenia, bipolar disorder and psychosis.

An individual can have different C4A gene copy numbers: typically, from 0 to 5 copies, with more Copy Number Variants (CNVs) associated with increased risk.

Identifying an individual's variation in C4A CNV can provide insight into risk for psychotic disorders and the potential for adverse drug reactions when using psychedelic drugs.

HaluGen’s genetic test identifies an individual’s C4A CNV to better identify those at risk for long-term adverse consequences that could potentially be triggered by psychedelic usage.

Address

Vancouver, BC

Website

http://www.halugen.com/

Alerts

Be the first to know and let us send you an email when HaluGen Life Sciences Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Vancouver?